Clinical Trials
19 trialsNCT05554406 2026-05-27
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06317649 2026-05-27
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05564390 2026-05-26
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05554393 2026-05-15
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT00658814 2026-04-30
Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01522976 2026-04-30
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04284787 2026-04-13
BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05554419 2026-04-13
Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT01349959 2025-04-27
Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02828358 2025-02-27
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
National Cancer Institute (NCI)
Phase 2 Completed
NCT03745352 2023-06-27
Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT01168219 2022-08-04
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT01281124 2019-09-24
Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01207726 2019-02-05
Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01935947 2018-07-27
Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00313586 2017-02-02
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT01105377 2014-08-01
Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01235117 2013-08-26
Azacitidine in Treating Patients With Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006019 2013-06-24
Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed